ANAVEX3-71-002 trial achieved its primary endpoint demonstrating safety and tolerability in both male and female adults Oral ANAVEX®3-71 tablet exhibits superior pharmacokinetics compared to the current immediate-release oral capsule, enabling once-daily dosing NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, sc ...

ANAVEX3-71-SZ-001 achieved its primary endpoint demonstrating safety and tolerability in adults with schizophrenia Encouraging trends observed in biomarkers support continued development NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, today announced positive topline res ...

SINGAPORE, Oct. 02, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumours, is pleased to announce the publication of a preclinical study, in a research article entitled “Donor-Derived Vγ9Vδ2 T Cells for Acu ...

STAFFORD, Texas, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Belgium. The Company's application to European regulators has been formally approved, adding Belgium as an approved country in FLAMINGO-01 in addition to S ...

Highlights: US Tariffs: Immuron does not anticipate any material impact from the recently announced US tariffs on pharmaceutical productsTravelan® Clinical Study: Topline results from the Travelan® clinical study conducted by Uniformed Services University are anticipated in October 2025 IMM-529 Regulatory Milestone: Immuron plans to submit an Investigational New Drug (IND) application to the U.S. FDA for IMM-529 (Clostridiodes difficile infection) in mid-October 2025ProIBS® Commercial Launch: The Australian ...

公司技术进展 - 公司报告其靶向化疗递送平台取得重大进展 [1] - 该新型技术是潜在的突破性靶向化疗递送平台 [1] - 技术旨在通过将有毒化疗药物定位在肿瘤内部及周围来解决关键的未满足需求 同时最大限度减少全身暴露 [1] 公司交易更新 - 公司提供了相关最终交易更新 [1] - 该平台及交易首次于2025年7月8日公布 [1]

公司股价表现 - Palisade Bio Inc (PALI) 股价大幅上涨83.77%至1.57美元 成交量达143,677,281股 [1] - Ouster Inc (OUSTZ) 股价上涨76.55%至0.09美元 成交量为150,580股 [2] - Ryvyl Inc (RVYL) 股价跃升72.64%至0.511美元 成交量高达231,813,941股 [3] - Klotho Neurosciences Inc (KLTOW) 股价上涨50.11%至0.14美元 成交量为134,508股 [4] 公司特定事件与业务 - Palisade Bio 宣布扩大承销公开发行 以每股0.70美元发行1.71亿股 筹集1.2亿美元资金 用于推进治疗自身免疫、炎症和纤维化疾病的新型疗法 [1] - Ouster 是一家高分辨率激光雷达传感器供应商 其技术服务于汽车、工业、机器人和智能基础设施等行业 [2] - Ryvyl Inc 前身为GreenBox POS 专注于基于区块链的支付解决方案 在软件基础设施领域展现潜力 [3] - Klotho Neurosciences 致力于开发针对关键健康问题的基因疗法产品 其肌萎缩侧索硬化疗法KLTO-202获得美国FDA孤儿药认定 [4] 行业与市场动态 - 股价大幅上涨的公司反映了行业的多样性 涵盖生物技术、医疗保健、技术和金融服务等领域 [5]

Basel, 1 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has commenced a tender offer for all of the outstanding shares of common stock of 89bio, Inc. (89bio) (NASDAQ: ETNB) at a price of $14.50 per share in cash, plus a non-tradeable contingent value right (CVR) to receive certain milestone payments of up to an aggregate of $6.00 per share in cash. The tender offer is being made pursuant to the previously announced merger agreement dated as of September 17, 2025, among Roche Holdi ...

SARASOTA, FL, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the purchase and sale of 2,857,143 shares of common stock at a purchase price of $0.875 per share. In a c ...

WALTHAM, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Sionna Therapeutics, Inc. (Nasdaq: SION), a clinical-stage biopharmaceutical company on a mission to revolutionize the current treatment paradigm for cystic fibrosis (CF) by developing novel medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, today announced that data will be presented at the 2025 North American Cystic Fibrosis Conference (NACFC) being held in Seattle, Washington on October 22-25, ...